Psychosis and schizophrenia
Browse by
Recent Submissions
-
The core deficit of classical schizophrenia: Implications for predicting the functional outcome of psychotic illness and developing effective treatments
(2019)Many people suffering from psychotic illnesses experience persisting impairment of occupational and social function. Evidence assembled since the classical description of schizophrenia over a century ago indicates that ... -
Prison vs. hospital for offenders with psychosis; effects on reoffending
(2019)With research showing a high prevalence of psychosis in prisons, its effective management is essential for clinical and criminal outcomes. In a matched sample of released prisoners and discharged patients with psychosis ... -
Attenuated post-movement beta rebound associated with schizotypal features in healthy people
(2019)Introduction: Schizophrenia and schizotypal personality disorder (SPD) lie on a single spectrum of mental illness and converging evidence suggests similarities in the etiology of the 2 conditions. However, schizotypy is a ... -
Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18 year-olds: Managing Adolescent first episode Psychosis: A feasibility study (MAPS)
(2019)BACKGROUND: Adolescent-onset psychosis is associated with more severe symptoms and poorer outcomes than adult-onset psychosis. The National Institute for Clinical Excellence (NICE) recommend that adolescents with first ... -
A meta-analysis taxonomizing empathy in schizophrenia
(2018)Background: Trait empathy is integral to relationship development and maintenance. Therefore, impairment in this ability can have an adverse effect on many domains of life including social, sexual, and marital. Previous ... -
The lost drugs of schizophrenia
(2019)This is a conference poster from the British Association for Psychopharmacology 2019 Summer Meeting, Manchester, 14-17 July 2019 -
Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study
(2019)BACKGROUND: There is a clinical concern that prescribing methylphenidate, the most common pharmacological treatment for attention-deficit hyperactivity disorder (ADHD), might increase the risk of psychotic events, particularly ... -
Schizophrenia, violence, clozapine and risperidone: A review
(1996)There is no longer much doubt that there is a small but real association between psychosis and violence directed at others, as well as between psychosis and self-directed violence, including suicide. Schizophrenia and the ... -
Electroconvulsive therapy for treatment-resistant schizophrenia
(2019)Background: Electroconvulsive therapy (ECT) involves the induction of a seizure by the administration of an electrical stimulus via electrodes usually placed bilaterally on the scalp and was introduced as a treatment for ... -
Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naive subjects with first-episode psychosis
(2019)Immunological abnormalities have been implicated in schizophrenia. On the other hand, antipsychotics may exert immunomodulatory effects, by triggering pro-inflammatory and anti-inflammatory agents through complex homeostatic ... -
Cognitive behavioral therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia
(2019)Cognitive behavioral therapy (CBT) is a psychosocial treatment that aims to help individuals reevaluate their appraisals of their experiences that can affect their level of distress and problematic behavior. CBT is now ... -
"Brain Connectivity Deviates by Sex and Hemisphere in the First Episode of Schizophrenia"—A Route to the Genetic Basis of Language and Psychosis?
(2019)Schizophrenia is genetic in origin and associated with a fecundity disadvantage. The deficits in schizophrenia have been attributed to variation related to the human capacity for language or brain laterality. How sex ... -
Personal growth in psychosis
(2019) -
Hyoscine for clozapine-induced hypersalivation: A double-blind, randomized, placebo-controlled cross-over trial
(2019)Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and ... -
Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia
(2018)- Background Cognitive behavioural therapy (CBT) is a psychosocial treatment that aims to help individuals re‐evaluate their appraisals of their experiences that can affect their level of distress and problematic behaviour. ... -
Serious mental health problems
(2018) -
The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions
(2012)The 3rd Schizophrenia International Research Society Conference was held in Florence, Italy, April 14–18, 2012 and this year had as its emphasis, “The Globalization of Research”. Student travel awardees served as rapporteurs ... -
Glutathione and glutamate in schizophrenia: a 7T MRS study
(2018)In schizophrenia, abnormal neural metabolite concentrations may arise from cortical damage following neuroinflammatory processes implicated in acute episodes. Inflammation is associated with increased glutamate, whereas ...
RSS 1.0